Clinical Trial Update: Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TAK-385 40 mg versus leuprorelin in endometriosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• Leuprorelin (leuprorelin)
• TAK-385

Snippet

Sponsor: ASKA Pharmaceutical Co., Ltd. | Conditions: Endometriosis | Phase 3 | Status: COMPLETED